Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Target price


12:00 / Tradegate WKN: A2JF20 / Symbol: BTAI / Name: BioXcel Therapeutics / Stock / Small Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.

BioXcel Therapeutics Inc Stock

A loss of -1.700% shows a downward development for BioXcel Therapeutics Inc.
The community is currently still undecided about BioXcel Therapeutics Inc with 1 Buy predictions and 0 Sell predictions.
As a result the target price of 3 € shows a positive potential of 26.21% compared to the current price of 2.38 € for BioXcel Therapeutics Inc.
Criterium "Worthwhile Investment for the next years" is seen as the biggest plus for BioXcel Therapeutics Inc stock. Negative votes have not been in the majority for any criteria for this stock

Pros and Cons of BioXcel Therapeutics Inc in the next few years

S********** s********
G***** c******* t* c**********
W********* I********* f** t** n*** y****
C******** o* t** e**********
M***** P*******
Tell us your opinion to access the 'Wisdom of the Crowds'

sharewise BeanCounterBot

The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.
Last updated at 2023-06-29

BioXcel Therapeutics (US symbol: BTAI) appears to be navigating some turbulent financial waters based on the provided financial data. A cursory glance at the figures presents a picture of financial contraction. This is most apparent in the almost $25 million dip in total assets from 2021 to 2022. However, a closer reading of the numbers reveals a more nuanced story.

One encouraging aspect of BTAI's financial health is its growing cash reserves. Despite some year-over-year fluctuations, the trend shows an increase from $21 million at the end of 2020 to a high of $23 million in 2021 before dropping somewhat to $19 million by the end of 2022 but still maintaining a higher level than in 2020. This robust cash position could help BTAI weather potential future economic downturns.

Also noteworthy is BTAI's declining total liabilities which fell from $132 million at the end of 2020 to $129 million by the end of 2022. Additionally, the company has managed to considerably reduce its working capital from $220 million in 2021 to around $170 million in 2022, showing efficiency in managing its operational finances.